Lumakras (Sotorasib)
- Medicine Name: Lumakras/Lumykras
- API: Sotorasib
- Dosage Form & Strength: Tablets: 320 mg, 240 mg, 120 mg.
- Manufactured By: Amgen Inc.
Lumakras/Lumykras (sotorasib) is an inhibitor of the RAS GTPase family indicated for:
- KRAS G12C-mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC): As a single agent, for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic NSCLC, who have previously been treated with at least one prior systemic therapy.
This indication is approved under accelerated approval based on ORR and DOR; continued approval depends on confirmatory trial results demonstrating clinical benefit.
- KRAS G12C-mutated Metastatic Colorectal Cancer (mCRC): In combination with panitumumab, for the treatment of adult patients with KRAS G12C-mutated mCRC, who have previously been treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.
Recommended Dosage:
- As a Single Agent for KRAS G12C-mutated Locally Advanced or Metastatic NSCLC: The recommended dosage of Lumakras/Lumykras is 960 mg (three 320 mg tablets or four 240 mg tablets or eight 120 mg tablets) orally once daily until there is evidence of disease progression or unacceptable toxicity.
- In Combination with Panitumumab for KRAS G12C-mutated mCRC: The recommended dosage of Lumakras/Lumykras is 960 mg (three 320 mg tablets or four 240 mg tablets or eight 120 mg tablets) orally once daily in combination with panitumumab until there is evidence of disease progression or unacceptable toxicity. Administer the first dose of Lumakras/Lumykras before the first panitumumab infusion.
Take the daily dose at the same time each day with or without food. Swallow tablets whole. Do not chew, crush, or split tablets. If any dose is missed by more than 6 hours, take the next dose as prescribed the next day. Avoid taking 2 doses at the same time to make up for the missed dose. If vomiting occurs after taking Lumakras/Lumykras, do not take an additional dose. Take the next dose as prescribed the next day.
- Monitor liver function tests (ALT, AST, and bilirubin) before initiating treatment, every 3 weeks for the first few months, and as clinically indicated thereafter. Withhold, reduce dose, or discontinue treatment in patients who develop significant elevations or hepatotoxicity.
- Monitor patients for new or worsening pulmonary symptoms such as cough, dyspnea, and fever. Immediately withhold treatment with this medicine in patients with suspected ILD or pneumonitis, and permanently stop if no other potential causes are noticed or if confirmed.
- Treatment with Lumakras/Lumykras may cause fetal harm when administered to pregnant women based on its mechanism of action. Advise pregnant women of potential risks to the fetus and recommend effective contraception during treatment and for a specified period after the last dose.
- There are no data on the presence of sotorasib in human milk or its effects on the breastfed child. Advise women not to breastfeed during treatment with this medicine and for at least 7 days after the final dose.
- The safety and effectiveness of this treatment in pediatric patients have not been established. Clinical studies have not included patients under 18 years; therefore, its use is not recommended in this population until further data are available.
What documents are required to import LUMAKRAS®/LUMYKRAS® to India?
LUMAKRAS/LUMYKRAS (sotorasib) tablets may be imported by patients or government hospitals in the patients’ names only.
The following documentation is required to import the product:
- A valid prescription from a qualified doctor.
- Patients diagnostic reports
- Patient ID proof (issued by the government of India)
How does the order get confirmed?
The order will be confirmed only after the receipt of:
- A valid prescription from the Doctor
- Import permit if applicable
Is LUMAKRAS®/LUMYKRAS® available in India?
LUMAKRAS/LUMYKRAS (sotorasib tablets) is a (prescription drug, prescription medication, or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.
IPN (Indian Pharma Network) facilitates the import of cancer medicines under named patient supply (NPS). Indian Pharma Network is the facilitator, providing input
- On the availability of Lumakras/Lumykras in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune, etc.)
- On availability in Gulf countries (Bahrain, Oman, Qatar, Kuwait, Iraq, Saudi Arabia, and the UAE).
- Lumakras/Lumykras price in India.
- Finding Genuine and reliable sources from the USA, Canada, Europe, and Australia
- Ensuring 100% transparency.
LUMAKRAS/LUMYKRAS can be made available to patients, doctors, and hospitals in Mumbai, Goa, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, and Pune, and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and an import permit.
IPN (Indian Pharma Network) can facilitate the supply of LUMAKRAS/LUMYKRAS (prescription medicines) to all locations in the world and India after fulfilling the legal requirements (if applicable).
Please contact us at WhatsApp: +91 98104 69557 | Toll-Free Number: 1800-1200-365 or write us at info@indianpharmanetwork.in for Lumakras/Lumykras cost in India.
We guarantee quality and delivery anywhere in the world as per the buyer’s requirements.
Indian Pharma Network is able to source the LUMAKRAS (Cancer Treatment Medicines) from across the globe, and has the ability to supply. Indian Pharma offers its customers worldwide access to the best available treatment.
Indian Pharma Network is able to dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient’s address only from New Delhi, India.
Are Lumakras and Lumykras the same medicine?
Yes, Lumakras and Lumykras are the same medicine. Both contain the active ingredient sotorasib. The difference lies only in branding and regional naming, with Lumakras used in the US and Lumykras in Europe and other markets.
What is the Generic Name for the trade name drug Lumakras/Lumykras®?
Sotorasib is the Generic Name for the trade name drug Lumakras/Lumykras®.
What is the Manufacturer’s Name of Lumakras/Lumykras®?
Lumakras/Lumykras® is manufactured by Amgen Inc.
Is Lumakras approved by the FDA?
Yes. Lumakras is approved by the FDA. Date of first approval: May 28, 2021.
What strengths and dosage forms are available for Lumakras® and Lumykras®?
Lumakras® is available as film-coated tablets for oral administration in strengths of 120 mg, 240 mg, and 320 mg.
Lumykras® is available as film-coated tablets for oral administration in strengths of 120 mg and 240 mg.
What are the most common side effects of Lumakras/Lumykras® Tablets?
As a single agent in NSCLC: diarrhea, musculoskeletal pain, nausea, fatigue, hepatotoxicity, and cough.
In combination with panitumumab in CRC: rash, dry skin, diarrhea, stomatitis, fatigue, and musculoskeletal pain.
How does Lumakras/Lumykras Import in India work?
Lumakras/Lumykras Import in India is possible through the Named Patient Program. This means the medicine can be imported for a specific patient with a valid doctor’s prescription. Indian Pharma Network helps manage the complete process, including approvals and delivery, making sure the medicine reaches the patient safely and legally.
Who is a reliable Lumakras/Lumykras supplier in India?
Indian Pharma Network is a trusted Lumakras/Lumykras supplier in India, facilitating compliant access through global sourcing channels and structured documentation support for eligible patients under applicable regulatory provisions.
How much does Lumakras/Lumykras® Tablet cost in India?
Lumakras/Lumykras® is not yet approved in India. However, patients in India can legally access it through the provision called the Named Patient Program (NPP). Lumakras/Lumykras prices may fluctuate over time because of market dynamics and regulatory changes. For the most transparent and latest Lumakras/Lumykras cost in India, please call/WhatsApp +91 98104 69557 or send an email to info@indianpharmanetwork.in.
Can Lumakras/Lumykras® Tablets be available in SAARC countries?
Apart from Gulf countries, Lumakras/Lumykras® Tablets can be accessed through import provisions like the Named Patient Program (NPP) in SAARC countries (India, Afghanistan, Maldives, Nepal, Bangladesh, Bhutan, Pakistan, and Sri Lanka). Indian Pharma Network (IPN) can help facilitate the legal supply of Lumakras/Lumykras® Tablets in these countries. We help provide legal access to this therapeutic drug through our reliable channels.
Is it safe to buy Lumakras/Lumykras® Tablets online in India?
Yes, one can buy Lumakras/Lumykras in India at the lowest price from the Indian Pharma Network (IPN) if this medicinal product is not yet registered or available in their country. We can help facilitate the supply of Lumakras/Lumykras® Tablets through legal channels.
Who is an authorized Lumakras/Lumykras importer in India?
Indian Pharma Network acts as a Lumakras/Lumykras importer in India, assisting with Named Patient Import processes, regulatory documentation, and compliant international procurement for patients requiring this therapy.
What are the storage conditions of Lumakras/Lumykras® Tablets?
Store the bottle of oral tablets at 20°C to 25°C (68°F to 77°F). Excursions permitted from 15°C to 30°C (59°F to 86°F).
Contact Patient Support
If you have any questions or need any help, contact our Patient Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.
Disclaimer
All Trademarks and Brands that appear on the website belong to their respective owners and indianpharmanetwork does not lay any claim on them we only provide Information.